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Abstract 
Solitary Fibrous Tumors (SFTs), rare soft tissue sarcomas that rely on several Epithelial-
Mesenchymal-Transition (EMT) protein regulators for invasion/metastatic progression. Curcumin 
(CUR) has several pharmacological activities, including anticancer activity and ability to suppress 
the EMT process. However, poor absorption, rapid metabolism and side effects at high doses limit 
the clinical applications of CUR. Here we present the results obtained by treating SFT cells with 
free CUR and three different CUR-loaded nanomicelles (NMs), each of which has its surface 
decorated with different ligands. All CUR-loaded NMs were more efficient in suppressing SFT cell 
viability and expression of EMT markers than CUR alone. Combined treatments with the pan-
histone deacetylase dual inhibitor SAHA revealed a differential ability in inhibiting EMT markers 
expression and SFT cell invasiveness, depending on the NM-ligand type. Finally, combinations of 
photodynamic therapy and CUR-loaded NM administrations resulted in almost complete SFT cell 
viability abrogation 24 hours after laser irradiation. 
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Background 
Solitary fibrous tumor (SFT) is a mesenchymal tumor of fibroblastic type1,2 in which the gene 
fusion NAB2-STAT6 has been identified as the molecular hallmark.3 Most SFTs present as well-
defined, slow-growing masses that can be cured by surgery. 10-20% of SFTs behave more 
aggressively, with local recurrence and/or distant metastasis for which systemic therapy is the 
clinical option.1,4-6 Advanced SFTs are more sensitive to the tyrosine kinase inhibitor (TKI) 
Sunitinib rather than to other TKIs (e.g., Sorafenib or Pazopanib)7-9 or to monoclonal antibodies 
(Bevacizumab).10 However, Sunitinib anti-tumor effect is transient, autophagy promoted by 
prolonged treatment likely acting as the mechanism leading to drug resistance.11 Also, SFTs are 
characterized by subpopulation of cells with stem-like properties notoriously refractory to 
chemotherapeutics.12 Literature suggests this cell pool may originate from fully differentiated cells 
via Epithelial-Mesenchymal-Transition (EMT), in which a series of protein hallmarks including 
SLUG, TWIST, EZH2, YY1 and integrinβ3 play a crucial role in invasion/metastatic progression.13  
The medicinal benefits of curcumin (CUR, Figure 1 left), a natural polyphenolic compound derived 
from Curcuma longa, are well known.14 Anti-inflammatory and antioxidant properties of CUR, 
along with immunomodulatory, proapoptotic, and antiangiogenic effects, are the main mechanisms 
underlying CUR anti-tumor activity. Moreover, CUR has a remarkable ability to negatively 
interfere with the EMT process in many cancer types.15 Regrettably, CUR low water solubility and 
poor pharmacokinetics are essential factors that severely curtail its effective application in cancer 
therapy.16,17 An obvious approach to circumvent these issues is the use of nanocarriers for CUR 
encapsulation, transport and delivery.17,18 In the synthetic nanovector arena, we reported a variety of 
self-assembled multivalent (SAMul) nanostructures which achieved high affinity binding to 
biological polyanions (e.g., DNA and heparin).19-26 We reasoned that the hydrophobic interiors of 
these SAMul nanomicelles (NMs) should be able to encapsulate CUR and deliver it to SFT cells, 
and this led to the design of this current study. In particular, we used a small family of SAMul 
entities (Figure 1 center) in which the ligand groups displayed on the surface of the relevant NMs 
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were subtly varied,23 in order to determine whether molecular-scale programming of the nanovector 
could have an impact on cellular uptake, release and subsequent anti-cancer activity of CUR.  
    
Figure 1. Chemical structure of curcumin (left), the three SAMul chemical entities DAPMA, SPD, and SPM (center), 
and of the pan-hystone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA, right). 
 
Accordingly, three different types of CUR-loaded SAMul NMs were prepared, characterized, and 
the relevant in vitro CUR release was measured. The effects of these three CUR-nanoformulations 
on SFT cells viability and invasiveness were assessed, and the expression of EMT markers was 
determined. 
Given the evidence that the NAB2/STAT6 fusion protein interacts with histone deacetylase2 
(HDAC2) activity in SFTs, the outcomes of an in vitro combined treatment with CUR-loaded NMs 
and the pan-HDAC inhibitor SAHA (Vorinostat)27 (Figure 1 right) were next investigated. Finally, 
as photodynamic therapy (PDT) is increasingly being recognized as an attractive, alternative 
treatment modality for superficial cancers,28 we surmised that combining PDT with CUR-NMs 
delivery could further potentiate CUR anticancer activity in SFT cells. Thus, CUR-NMs/PDT 
combined treatments were also carried out. All experiments described above were performed in 
parallel using free CUR, and the relative performance of free- and nano-delivered CUR is presented 
and discussed. 
 
Experimental Section 
Reagents 
Culture media Dulbecco’s Modified Eagles Medium (DMEM) and its supplements containing 
antibiotics and fetal bovine serum (FBS) were purchased from Gibco Invitrogen Corporation 
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(USA). Curcumin and SAHA were purchased from Sigma Aldrich (Italy). 
Stabilized SFT cell line 
The primary SFT cell line was stabilized by retroviral delivery of SV40 large T-antigen (pwzl-neo 
large T-Ag) performed in accordance with standard procedures.11 The nuclear expression of STAT6 
in formalin fixed paraffin embedded (FFPE) cells was verified by immunohistochemistry (IHC).  
Synthesis of DAPMA, SPD, and SPM-based self-assembling amphiphilic molecules 
C16-N,N-di-(3-aminopropyl)-N-methylamine (DAPMA), C16-spermidine (SPD), and C16-spermine 
(SPM) SAMul molecules were available from our previous work. Their synthesis, purification and 
characterization are reported in detail in our previous work.23 
Preparation of CUR-loaded nanomicelles 
 DAPMA, SPD, and SPM nanomicelles (NMs) used to encapsulate CUR were obtained by the film 
dispersion method.19 Accordingly, 0.32 mg of CUR were dissolved in 1 mL of mixed solvent 
(chloroform:methanol = 3:2) (vol/vol). The drug was then mixed with 3 mg of DAPMA, SPD, or 
SPM, respectively, in 3 mL of mixed solvent. The solvent was removed by vacuum rotary 
evaporation to form a dry film. The dried film was then hydrated with HEPES buffer (10 mM, pH 
7.4) at 60°C for 30 minutes under stirring. Free CUR was separated by filtration through 0.45 µm 
polycarbonate membrane (Millipore Co., USA). Incubation overnight at 4°C was followed by 9 
hours of dialysis (changing distilled water every hour) using a membrane with molecular weight 
cut-off of 2000 Da. The product in the dialysis tube was then lyophilized (SpeedVac, Thermo 
Fisher, USA). CUR encapsulation efficiency in each micelle type (%, = (weight of loaded CUR 
/total CUR weight) x 100)19 was quantified by UV-vis spectroscopy (Ultrospect 3100PRO, 
Amersham Biosciences, UK) at 420 nm. 
Characterization of NMs Using Dynamic Light-Scattering (DLS) 
The size distribution and zeta potential of empty and CUR-loaded NMs were determined by DLS 
measurements using a Zetasizer Nano-ZS (Malvern, UK). All reported experimental results were 
performed in triplicate and reported as mean value ± standard deviation (SD). 
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In vitro CUR release 
The release of CUR from DAPMA, SPD and SPM loaded NMs was performed using the dialysis 
method. Accordingly, a known quantity (1.0 mg/mL) of each CUR-loaded NM was dispersed in 10 
mM PBS at pH 7.4 and then transferred into the dialysis membrane tubes (molecular weight cut-off 
3000 Da). Since CUR is only sparingly soluble in aqueous media, the release study was carried out 
by immersing the tube in a beaker containing 50 mL of 50:50 (v/v) methanol: water solution to 
facilitate sink-like conditions and stirred constantly at 37 °C for 0, 1, 2, 4, 6, 8, 10, 12, and 24 h. At 
each time point, 1 mL of solution was withdrawn from the release medium and replaced with fresh 
PBS. CUR content was again determined using the UV-vis DS11-FX spectrophotometer (DeNovix 
Inc., USA) at 420 nm. 
Cell treatments with CUR and CUR-loaded NMs 
The SFT cell line was grown in DMEM containing 5%FBS. Cells were maintained as monolayer in 
a humidified atmosphere (5% CO2, 37°C). After 72h, culture medium was replaced with treatment 
medium containing different concentrations of free or CUR-loaded NMs. 
Combined CUR/SAHA and CUR-loaded NMs/SAHA treatments 
Suberoylanilide hydroxamic acid (SAHA) was added to CUR or CUR-loaded NM treatments of 
SFT cells. Optimal SAHA concentration for combination experiments was determined by 
dispensing SFT cells with 5 µM of SAHA for 24 and 48h (5% CO2, 37°C). 
SFT cell CUR uptake and phalloidin immunofluorescence (IF) in combined treatments 
SFT cells (3x105) were seeded in each plate using DMEM supplemented with 
Penicillin/Streptomycin/Gentamicin/10%FBS and incubated (37°C, 5% CO2) for 3 days before any 
treatment, without medium restoring. Autoclaved coverslips were added to each plate in order to 
allow cells to grow on them. SFT cells were treated as described above with CUR, CUR-loaded 
NMs, and SAHA. The last day of treatment, coverslips were removed and then fixed with methanol 
(CUR uptake assay) or paraformaldehyde (phalloidin staining). The distribution of CUR inside SFT 
cells was observed by fluorescence microscopy at an excitation wavelength of 488 nm. Phalloidin 
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(1:200 in DPBS, 2 hours incubation, Alexa Fluor) was used to observe actin fiber changes after 
SAHA treatments. DAPI (blue signal) was used to counterstain nuclei. Representative fields were 
captured with a DM6000FS fixed stage fluorescence microscope (Leica, Germany). 
Cell viability assays 
Cell viability was determined by the 3-(4,5 dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide 
(MTT, Sigma Aldrich, Italy) assay. Cultures were initiated in 96-wells plates at a density of 5×103 
cells per well. After 72 h incubation, cells were treated with different concentrations of free CUR, 
CUR-loaded NMs, or combined treatment dosed and cultured for 24 h. Next, 20 µL of MTT reagent 
was added to each well and incubated for 4h at 37°C, 5% CO2 in the dark. The supernatant was 
aspirated and then 100 µL of DMSO were added under gentle stirring. The absorbance per well was 
measured at 550 nm (Infinite M1000, TECAN, Switzerland), and normalized to the absorbance of 
wells containing untreated cells. The cytotoxicity of blank DAPMA, SPD, and SPM NMs in two 
non-cancer cell lines (normal human primary lung fibroblasts, HLF, ATCC® PCS-201-013, and 
normal human primary prostate epithelial cells, HPrEC, ATCC® PCS-440-010, ATCC, Manassas 
VA, USA) was also evaluated by the MTT assay. To this purpose, cells were seeded and incubated 
with 75 µM, and 100 µM of each blank NM under the same experimental conditions. All 
cytotoxicity results were obtained from three independent measurements and are expressed as mean 
value ± standard deviation (SD). 
Invasion assay 
Transwell membrane (Corning, Japan) coated with matrigel (BD Biosciences, USA) was used for 
the invasion assay.29 After collecting and centrifuging, SFT cells were re-suspended at 1.25x105 
cells/mL. Then, 2 mL of cell suspension (2.5x105 cells) were seeded to upper wells of pre-coated 
Transwell chambers. Cells were then incubated with 10 µM, 20 µM and 50 µM CUR re-suspended 
in DMEM. DMEM alone was used as control. In parallel, 500 µL of DMEM+10%FBS was placed 
in the lower chambers as a chemo-attractant. After 24 h incubation, cells in the upper chamber were 
removed, fixed in methanol and stained with crystal violet. Finally, cells attached through the 
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matrigel were counted in five random (center and borders) microscope fields (200x), and averaged. 
Biochemical analyses 
Proteins were extracted as previously described.30 Protein (20 µg of total protein lysate per sample) 
was subjected to western blot (WB) analysis using standard protocols. EZH2 (#5246) and SLUG 
(#9585) antibodies were purchased from Cell Signaling Technology (USA); YY1 (ab109237), 
integrinβ3 (ab75872) and c-myc (ab32072) antibodies were obtained from Abcam (USA). Actin 
(A2228), used to normalize protein expression, was purchased from Sigma Aldrich (Italy). The 
secondary antibodies anti-rabbit and anti-mouse were purchased from Santa Cruz Biotechnology 
(USA). 
CUR and CUR-NMs/photodynamic therapy (PDT) combined treatments 
SFT cells incubated with free CUR and CUR-loaded NMs at the same concentrations employed in 
the toxicity assays reported above were exposed to a 445 nm blue laser light (power density 150 
mW/cm2, estimated average fluency of 9 J/cm2) (Klaser, Eltech K-Laser, Italy). The distance 
between the laser and the 96-wells plates was optimized to enable an identical distribution of light 
on each well. Further non-irradiated 96-well plates were used as control). After laser treatments, 
cells were kept at 37°C, 5% CO2 for 1 h. Then, 10 µM 2’,7’-dichlorofluorescin diacetate (Thermo 
Fischer Scientific, USA) were added to each well, followed by 30 minutes incubation at 37°C, 5% 
CO2 to evaluate Reactive Oxygen Species (ROS) production. The dye solution was then replaced 
with Dulbecco’s Phosphate Buffered Saline (DPBS, Sigma Aldrich, Italy) and plates were read by 
means of a fluorescence spectrophotometer (EnVision, 2104 Multilabel Reader, PerkinElmer, USA) 
at 520 nm. Moreover, MTT analyses were carried out on the same plates after DPBS washing. 
 
Results 
Free CUR treatments reduce SFT cell viability and EMT-markers expression 
Free CUR uptake by SFT cells was confirmed by fluorescence microscopy (Figure 2A, left). The 
intensity of the green fluorescent signal proportionally increased with increasing concentrations of 
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CUR (Figure 2A, right). A concentration-dependent cell viability behavior was observed (Figure 
2B): 10 µM treatment induced no variation in cell viability, 20 µM resulted in a minimal decrease 
in cell viability, while 50 µM drastically reduced the number of viable cells to less than 20%. Also, 
10 µM free-CUR exposure resulted in a 50% reduction in cell invasion, while a 99% reduction was 
achieved with 50 µM CUR (Figure 2C). Concomitantly, the expression of the EMT markers was 
significantly reduced after CUR treatment (50 µM, 24 h) (Figure 2D). Of note, c-Myc and SLUG 
expression was already reduced after 24 h treatment with 20 µM CUR, and the low expression of 
these two proteins was maintained in the second day of treatment (Figure 2D).  
 (A) 
  (B) 
   (C)  (D) 
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Figure 2. SFT cells treated with CUR. (A) Left: representative confocal images of free CUR uptake (24 hr) in SFT cells 
stained with red (WGA Alexa Fluor 546) for plasma membranes and blue (DAPI) for nuclear counter-stain. CUR auto-
fluorescence captured at 488 nm (green) wavelength (magnification 40x). Right: quantitative analysis of the green 
signal intensity for the images in the right panel. NT _= non-treated cells. Data represent the average of three 
independent experiments ± the standard deviation. (B) Viability of SFT cells (24 h) treated with CUR. NT: non-treated 
cells. (C) Representative fields of invasive SFT cells on membrane (magnification 200X, left panel) and average 
number of migratory cells per field (right panel) after CUR treatment. Data represent the average of three independent 
experiments ± the standard deviation. (D) WBs for EMT marker expression (actin as control) after CUR treatment. 
Actin is used as control. 
Preparation and physico-chemical characterization of CUR-loaded NMs 
The compounds DAPMA, SPD, and SPM used in this work bore a different, positively charged 
ligand moiety coupled to a C16-alkyl chain23 (Figure 1B). Using the film dispersion method, all 
three molecules formed similar-sized nanoassemblies, both in the absence and presence of CUR, as 
detected by DLS (Figures 1SA-F). The NM average dimensions and their zeta-potentials were only 
slightly affected by CUR encapsulation (Table 1S). The drug-encapsulation efficiency (EE, %) and 
the drug loading capacity (DL, %) of all three NMs were also comparable (EE = 10-13% and DL = 
11-16% Table 1S). All three NMs consistently showed lower CUR release when compared to free 
CUR (Figure 2S): while approximately 91% of CUR was released in the first 6 hours of dialysis, 
only 43 to 50 % of the loaded CUR was released from the three loaded NMs in the same time 
interval. The cumulative release of CUR from the DAPMA, SPD, and SPM NMs was 78.31 ± 
3.18%, 77.23 ± 4.11%, and 66.83 ± 5.02%, respectively.  
Nanomicelles loaded with CUR are more effecting in reducing cell viability and invasiveness  
The amount of CUR detected inside SFT cells after NM delivery was comparable to that observed 
upon treatment with free CUR at 50 µM. Notably, however, the nominal CUR concentrations 
actually being administered in the case of NMs were considerably reduced (Figure 3A). At any 
given drug concentration, all three CUR-loaded NMs were remarkably more effective in their 
cytotoxic activity than the corresponding free-CUR system (Figure 3B). Additionally, the viabilities 
of SFT and two non-cancer cell lines cultured in the presence of all three blank NMs were in the 
range 79-93% at the highest concentration tested (100 µM, Figure 3C); accordingly, the three NMs 
are endowed with little intrinsic cytotoxic activity in their own right. 
CUR-loaded NMs also inhibited cell invasiveness; yet, in this case cell invasiveness inhibition was 
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induced at much lower CUR concentrations (Figure 3 D-F). The inhibition of SFT cell migration by 
CUR-SPM (500 nM) was somewhat less effective than that achieved with CUR-DAPMA and 
CUR-SPD delivering the same CUR concentration, in line with the slower CUR release (Figure 2S) 
and the lower SFT cytotoxic effect associated with the CUR-SPM nanomicelles (Figure 3).  
(A) 
(B)  (C) 
  (D) 
       (E) 
       (F) 
Figure 3. SFT cells treated with CUR-loaded NMs. (A) Confocal images of NM-delivered CUR uptake in SFT cells 
(conditions as in Fig. 2A). (B) Viability of SFT cells (24 h) treated with CUR-DAPMA (dark blue), CUR-SPD (dark 
green), CUR-SPM (dark plum) NMs and free CUR. NT = non-treated cells (green bar). (C) Cytotoxicity of blank 
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DAPMA (patterned dark blue), SPD (patterned dark green) and SPM (patterned dark plum) NMs in SFT (vertically 
striped bars) and two non-cancer cell lines: normal human primary lung fibroblasts (HLF, horizontally striped bars) and 
normal human primary prostate epithelial cells (HPrEC, diagonally striped bars). Representative fields of invasive cells 
on membrane (magnification 200X, left panels) and average number of migratory cells per field (right panels) after 
CUR-DAPMA (D), CUR-SPD (E), and CUR-SPM (F) NM treatments. NT = non-treated cells. Data represent the 
average of three independent experiments ± the standard deviation. 
 
 
Inhibition of EMT markers expression 
WB analyses (Figure 4) revealed that SFT cells treated with CUR-loaded NMs expressed different 
amounts of EMT markers. CUR-DAPMA and CUR-SPD NMs treated cells expressed significantly 
lower amounts of EZH2 compared with those receiving CUR-SPM. Similarly, YY1 expression was 
slightly reduced after 1µM CUR-DAPMA and CUR-SPD treatments but not by CUR-SPM. This is 
in agreement with the results above which suggested that SPM was a less effective delivery vehicle 
for CUR. Notably, CUR-SPD was the only system able to strongly inhibit c-Myc expression. On 
the other hand, SLUG expression was abolished after treatment with all three different NMs. 
Finally, integrin β3 expression was exclusively affected by CUR-SPD treatment. Overall, the CUR-
SPD system appears to be the most effective drug-NM combination in terms of inhibiting the 
expression of EMT markers.  
   
Figure 4. Western blots for EMT markers expression following treatments with CUR-DAPMA (left), CUR-SPD 
(center), and CUR-SPM (right) NMs. Actin is used as control. 
 
Free CUR and SAHA combined treatments 
In order to verify any synergistic effect between the cytotoxic action of CUR and the HDAC 
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inhibitor SAHA, combination experiments were performed. After 24h of combined treatment, no 
significant reduction in SFT cell viability was observed. Extending treatment to 48h revealed that, 
while SAHA exerted a weak dose-dependent cytotoxic effect per se (EC50 = 2.7 µM), when co-
administered with CUR this effect was reversed, particularly at the highest CUR dose (Figure 5A).  
Phalloidin IF carried out after SAHA/CUR combined treatment underlined a partial reversal of the 
mesenchymal phenotype, evidenced by a shift from spindle shaped cells with visible actin stress 
fibers to predominantly cuboidal shape cells after 24 h of treatment (Figure 5B-D). CUR combined 
with SAHA showed no increase in therapeutic efficacy when compared with the corresponding 
CUR treatment alone (Figure 5E). To determine whether SAHA could enhance the effect of CUR 
on HDAC2 and MMP2 expression, 5 µM SAHA was administered in combination with different 
CUR concentrations for 24-48 h. The combined treatment increased both HDAC2 and MMP2 
levels. On the other hand, SAHA alone led to a decrease of MMP2 expression (Figure 5F). 
 (A) 
  (B) 
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Figure 5. SFT cells treated with CUR/SAHA. (A) Viability of SFT cells (24 h) treated with different SAHA 
concentrations (marked on the x-axis) alone (pink bars) or combined with CUR (10 µM, yellow bars; 20 µM, orange 
bars, and 50 µM, red bars). NT = non-treated cells (green bar). Morphological change of SFT cells induced by SAHA, 
CUR and combined treatments (CUR /SAHA) after 24/48 h visualized by phalloidin IF (Green (Alexa Fluor 488): actin 
filaments; blue (DAPI): nuclear counter-staining, representative fields, magnification 100X): (B) non-treated cells (left), 
CUR -/SAHA 5 µM (right). (C) CUR 10 µM/SAHA - (left), CUR 20 µM/SAHA - (center), CUR 50 µM/SAHA - 
(right). (D) CUR 10 µM/SAHA 5 µM (left), CUR 20 µM/SAHA 5 µM (center), CUR 50 µM/SAHA 5 µM (right). (E) 
Suppression of SFT cells invasiveness by CUR alone and in combination with SAHA: representative fields of invasive 
cells on membrane (magnification 200X, left) and average number of migratory cells per field (right). CUR, orange 
bars; CUR/SAHA: orange-pink checked bars. NT = non-treated cells (green bar). Data represent the average of three 
independent experiments ± the standard deviation. (F) Western blots for HDAC2 and MMP2 expression following CUR 
alone (left) and combined CUR/SAHA (right) treatments. Actin was used as control. 
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CUR-NMs and SAHA combined treatments 
To determine the sensitivity of SFT cells to the cytotoxic/cytostatic effects of the combined CUR-
NM/SAHA treatment, cells were incubated with the three CUR-loaded NMs in combination with 5 
µM SAHA for 24 h. Unlike free CUR/SAHA (Figure 6A), the SAHA/CUR-SPD combined 
administration induced cell death (Figure 6B). Moreover, on 24h treatment with SAHA/CUR-SPD, 
the SFT cells exhibited partial reversal of the mesenchymal phenotype, characterized by a shift 
from spindle shaped cells with visible actin stress fibers to predominantly epithelial-like shape cells. 
Phalloidin signal intensity progressively decreased after treatments while SFT cells assumed more 
epithelial-like features before death (Figure 6D-F). Conversely, the combined SAHA/CUR-
DAPMA and SAHA/CUR-SPM treatments stimulated cell growth (Figure 6B-C). 
CUR-SPD and CUR-SPM NMs, administered in combination with SAHA, also significantly 
inhibited cell invasiveness compared to untreated samples. Contrarily, after SAHA/CUR-DAPMA 
combined treatment the number of cells endowed with invasive potential remained very high 
(Figure 6G-I). This was an unexpected result, since treatment with CUR-DAPMA alone had 
abolished this invasiveness (Figure 3D). 
Lastly, while all three CUR-loaded NMs did not significantly affect the expression of HDAC and 
MMP2 per se (Figure S3), the combined treatment SAHA(5 µM)/CUR-DAPMA(1 µM) reduced 
HDAC2 expression. In contrast, HDAC2 expression levels were not affected by SAHA/CUR-SPD 
or SAHA/CUR-SPM treatments at the same concentrations, while HDAC2 expression increased 
after treatment with SAHA (5 µM) alone or in combination with CUR-SPD (500 nM). MMP2 
expression decreased after all SAHA/CUR-NM combined treatments. In particular, a significant 
decrease in MMP2 expression was observed after administration of SAHA/CUR-SPD and 
SAHA/CUR-SPM (Figure 6J-L). 
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   (F) 
 (G) (H) (I) 
(J)      (K)  
(L) 
Figure 6. SFT cells treated with CUR-loaded NMs/SAHA. Viability of SFT cells (24 hr) treated with SAHA alone 
(pink bars), (A) CUR-DAPMA alone (dark blue bars) and in combination with SAHA (dark blue/pink checked bars); 
(B) CUR-SPD alone (dark green bars) and in combination with SAHA (dark green/pink checked bars); (C) CUR-SPM 
alone (dark plum bars), and in combination with SAHA (dark plum/pink checked bars). NT = non-treated cells (green 
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bars). Morphological change of SFT cells induced by combined SAHA/CUR-DAPMA (D), SAHA/CUR-SPD (E), and 
SAHA/CUR-SPM (F) treatments after 24h and 48h visualized by phalloidin IF (Green (Alexa Fluor 488): actin 
filaments; blue (DAPI): nuclear counter-staining, representative fields, magnification 100X). Suppression of SFT cells 
invasiveness by combined SAHA/CUR-loaded NMs treatments: average number of migratory cells per field after 
SAHA/CUR-DAPMA (G), SAHA/CUR-SPD (H), and SAHA/CUR-SPM (I) administrations. NT = non-treated cells 
(green bars). Data represent the average of three independent experiments ± the standard deviation. Western blots for 
HDAC2 and MMP2 expression following treatments with SAHA alone and in combination with CUR-DAPMA (J), 
CUR-SPD (K), and CUR-SPM (L). Actin is used as control.. 
 
Photodynamic therapy (PDT) treatments 
To evaluate the phototoxic potential of combined CUR or CUR-loaded NMs and blue laser 
treatments, the generation of ROS was also investigated. At T0, no significant induction of ROS 
was detected after treatment with different CUR concentrations; concomitantly, a moderate increase 
in ROS production was assessed by administering CUR in association with laser irradiation, 
particularly at high CUR concentrations (Figure 7A). This had an impact on cell viability, which 
reduced on combined CUR/laser treatment (Figure 7B). High ROS levels were detected in the same 
experiments performed at T0 with the CUR-loaded NMs. Indeed, CUR-DAPMA administration 
(with/without laser) resulted in significant ROS generation (Figure 7C) which, in turn, decreased 
cell viability (Figure 7F). The combined C16-SPD or C16-SPM NMs and laser irradiation treatments 
also resulted in a modest increase in ROS generation compared to the corresponding no-laser 
experiments (Figure 7D-E). Notably, C16-SPD and C16-SPM 1µM treatments decreased cell 
viability with/without laser, while treatments with these two NMs loaded with 500 nM CUR 
showed an increase in cell viability compared to untreated samples (Figure 7G-H).  
Cell viability assays carried out after 24 h (T24) revealed that a single exposure to blue laser led to a 
considerably cell viability reduction per se (Figs. 7I-L). After CUR treatment with laser irradiation, 
this cell viability decline was further induced (Figure 7I) to levels comparable to those achieved 
upon NMs treatment without laser exposure. Low doses of CUR-loaded NM treatments combined 
with laser blue light dramatically reduced cell viability (Figure 7J-L). For comparison, such low 
cellular vitality values could be achieved only by administering high doses of free CUR (Figure 7I). 
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(A)   (B) 
 (C)  (D) (E) 
 (F)  (G)  (H) 
 (I)    (J) 
 (K)   (L) 
Figure 7. SFT cells treated with CUR or CUR-loaded NMs combined with PDT. Quantification of ROS generation 
immediately after treatment (T0) (A), and cell viability (B) after CUR alone (orange bars) and CUR/PDT combined 
Page 19 of 28
ACS Paragon Plus Environment
Molecular Pharmaceutics
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
  
treatments (orange/white checked bars). T0 quantification of ROS generation (C,D,E) and cell viability (F,G,H) after 
CUR-DAPMA alone (dark blue bars) and CUR-DAPMA/PDT combined treatments (dark blue/white checked bars), 
CUR-SPD alone (dark green bars) and CUR-SPD/PDT combined treatments (dark green/white checked bars), and 
CUR-SPM alone (dark plum bars) and CUR-SPM/PDT combined treatments (dark plum/white checked bars). Cell 
viability at 24 h (T24) after CUR alone (orange bars) and CUR/PDT combined treatments (orange/white checked bars) 
(I), CUR-DAPMA alone (dark blue bars) and CUR-DAPMA/PDT combined treatments (dark blue/white checked bars) 
(J), CUR-SPD alone (dark green bars) and CUR-SPD/PDT combined treatments (dark green/white checked bars) (K), 
and CUR-SPM alone (dark plum bars) and CUR-SPM/PDT combined treatments (dark plum/white checked bars) (L). 
NT = non-treated cells. Data represent the average of three independent experiments ± the standard deviation. 
 
Discussion 
Conventional chemotherapy is effective in controlling/stabilizing locally advanced/metastatic 
SFTs,6 but suffers from numerous side effects, resistance, and has not significantly improved 
patient survival thus far. Thus, non-toxic, more selective agents are urgently needed to treat SFTs. 
CUR is known to exert anti-cancer activity via its effect on several biological pathways involved in 
mutagenesis, oncogene expression, cell cycle regulation, apoptosis, tumorigenesis, tumor growth, 
angiogenesis, and metastasis.31 Here, we explored the activity of CUR (both in its free and 
nanovector-encapsulated form) on a stable SFT cell line. Initially, the sensitivity of SFT cells to free 
CUR was evaluated in vitro. The results obtained show a dose-dependent reduction in cell viability 
upon increasing CUR concentration (Figure 2A-C); yet, a significant reduction in the expression of 
key EMT markers could only be achieved at high CUR doses (50 µM, Figure 2D). Unfortunately, 
such CUR concentrations can induce heavy side effects in vivo. The application of CUR-loaded 
NMs resulted in a drastic decrease in cell viability and expression of the EMT markers32 at 
substantially lower doses of active principle with respect to free CUR administration (Figures 3 and 
4). Once inside SFT cells, the three CUR-loaded NMs interact with the pathways involved in EMT 
in different ways. CUR-DAPMA and CUR-SPD were again the most effective NMs in reducing the 
expression of all EMT markers except for integrin β3 which, in the case of CUR-DAPMA, 
exhibited expression levels comparable to those observed in untreated samples. CUR-SPD 
treatments induced inhibition of all EMT protein expression at 24 h, while CUR-DAPMA treatment 
required at least 48 h to obtain a reduction of YY1 and c-Myc expression. Conversely, CUR-SPM 
treatment resulted in a decrease of YY1, c-Myc and SLUG proteins but did not affect EZH2 and 
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integrinβ3 expression even after 48 h (Figure 4). Notwithstanding similar CUR release profiles for 
the three NMs were obtained in vitro (Figure 2S), their distinctive chemico-physical features might 
induce different drug release once inside the cells, ultimately leading to distinct interactions 
between target proteins and CUR. It is, nonetheless, clear that molecular-scale programming of the 
SAMul NM delivery vehicle plays a direct role in tuning its biological performance within the cell, 
which suggests such systems can undergo significant structure-activity effect optimization to open 
up a range of potential applications against different therapeutic targets. In this case, CUR-SPD 
appeared to be the optimal system in terms of its activity. The observations that CUR-loaded NMs 
dramatically decreased the levels of EMT marker expression is encouraging, and represents an area 
of investigation currently in progress in our laboratories. 
Results from invasion assays demonstrate that all CUR-loaded NMs were significantly more 
effective in inhibiting SFT cell invasion (Figure 3D-F) than CUR alone (Figure 2C). One of the key 
factors associated with cancer cells invasion and metastasis is the overexpression of matrix 
metalloproteinase2 (MMP2), an endopeptidase capable of digesting the extracellular matrix. HDAC 
inhibitors such as SAHA, which targets HDAC2 and MMP2, are promising therapeutic agents 
currently in cancer clinical trials.33 Since the NAB2/STAT6 fusion protein interacts with HDAC2 
activity in SFTs,3,34 CUR/SAHA and CUR-loaded NMs/SAHA combined treatments of SFT cells 
were performed. SAHA alone or in combination with CUR did not significantly affect SFT cell 
viability (Figure 5A); on the other hand, SAHA induced down-regulation of MMP2 expression 
compared with the combined CUR treatment (Figure 5D). Similarly to EMT marker expression, the 
use of NMs led to a significantly stronger reduction of MMP2 expression (Figure 6J-L). In 
particular, CUR-SPD and CUR-SPM NMs were able to reduce the expression of MMP2 within 
24h, thereby abrogating the invasion rate of SFT cells (Figure 3D-F). Low expression of MMP2 
correlates with fewer tumor cells showing invasive behavior; thus, it is tempting to speculate that, 
should CUR-SPD and CUR-SPM NMs be able to suppress MMP2 expression in vivo, this might 
translate into inhibited SFT cell invasive behavior and reduced potential for metastasis. According 
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to the results in Figure 5L, CUR-DAPMA seemed to have a greater impact on HDAC2 expression 
(24 h) than on MMP2 expression (48 h). Therefore, we suggest that CUR-DAPMA NMs and 
SAHA might be likely involved in a synergistic inhibition of HDAC2.  
The most interesting and unexpected effect of SAHA treatment was the morphological change of 
the tumor cells. After treatment with SAHA alone or in combination treatments, SFT cells exhibited 
a more epithelial-like shape (Figure 5B). Previous studies demonstrated that SAHA treatment can 
induce morphological changes in an osteosarcoma cell line and reduce invasiveness.35 Here, the 
cytotoxic activity of CUR-loaded NMs (Figure 6D-F) prevented the detection of cytoskeleton 
variations as observed in the previous experiments with free SAHA and CUR. SAHA trials in 
patients with solid tumors have produced conflicting results,36 in which this compound exerts both 
pro- and anti-apoptotic pathways. However, based on the evidence that SAHA stabilizes disease 
and elicits partial responses in patients, SAHA remains in clinical trials as a component of multi-
drug therapies.37 Our data unambiguously show that SAHA could inhibit markers of metastasis 
(MMP2) and SFT cell invasiveness in CUR-SPD and CUR-SPM NMs combined treatments, while 
the SAHA/CUR-DAPMA combination tended to increase the aggressive behavior of cancer cells. 
Once again, CUR-SPD emerges as a promising delivery system, this time in combination with 
SAHA. These results undoubtedly deserve further studies aimed at defining the specific pathways 
activated by each MN type. In addition, the effect of SAHA should be tested on other sarcoma cell 
lines to determine an eventual rationale, still unknown, able to explain how SAHA can induce both 
pro- and anti-apoptotic pathways. 
The use of photodynamic therapy (PDT) is steadily growing as an innovative/promising approach in 
cancer therapeutics. Generally, the systemic toxicity of chemotherapeutic drugs can be reduced 
using PDT38 which is employed in order to activate the cytotoxic effect at the desired site of action. 
Specifically, Koon and colleagues reported that CUR cytotoxicity is enhanced by blue light laser 
application in nasopharyngeal cancer cell lines39 by virtue of the drug’s potential to generate 
reactive oxygen species (ROS) on irradiation40 which, in turn, plays an important role in controlling 
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proliferation and apoptosis.41 In the last part of this study we investigated the combined effect of 
PDT and CUR administrations on cell viability using both free and NM-encapsulated drug. SFT 
cells were found to be more sensitive to the combined CUR/PDT treatments, which exerted a 
specific reduction of proliferative potential. Treating SFT cells using CUR doses of up to 50 µM in 
combination with laser revealed a concentration-dependent viability reduction immediately after 
irradiation (Figure 7A-B). Experiments carried out using PDT and CUR-loaded NMs combination 
treatment resulted in almost complete cell viability abrogation 24 h after laser irradiation (Figure 7J-
L) at much lower CUR concentrations, demonstrating the potential of these NM delivery vehicles to 
be effectively combined with PDT.  
In summary, the present study establishes the importance of adopting effective nanocarrier systems 
to efficiently deliver CUR to SFT cells, achieve substantial cytotoxic activity, affect EMT markers 
expression and decrease cancer cell invasiveness. Intriguingly, the molecular-scale programming of 
the surface ligands on the NM delivery vehicle, changes which are relatively subtle in nature, 
significantly modified the biological activity, with CUR-SPD generally being the most effective 
system. In combination with SAHA, CUR-SPD suppressed MMP2 expression, lowering the 
aggressive nature of the tumor, and hence its metastatic potential. Moreover, an approach based on 
combining CUR-loaded NMs and blue laser PDT treatment led to very promising results, with laser 
light addition resulting in almost complete loss of cell viability when using CUR-NM delivery 
systems. Since the proposed NM formulations showed great potential in vitro, further studies 
focusing on determining the mechanisms underlying the different pharmacological response  and 
EMT marker expression inhibition elicited by our CUR-loaded NMs are currently ongoing in our 
laboratories and will be reported soon. If successful, these studies will warrant future investigations 
establishing pharmacokinetic profile and cytotoxic effects of these systems in vivo (i.e., animal 
models). Finally, it is also worth noting that in addition to binding a drug such as CUR in the 
hydrophobic interior, the surface ligands of these NMs can be used to bind biomolecular drug 
cargoes (e.g. nucleic acids). This opens the potential of dual therapies in which such carriers are 
Page 23 of 28
ACS Paragon Plus Environment
Molecular Pharmaceutics
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
  
used to deliver two different active agents into tumor cells. Work towards such multidrug therapies 
is currently underway.  
 
Supporting information 
Size distribution (DLS) of CUR-DAPMA, CUR-SPD, and CUR-SPM nanomicelles (Figure S1); 
Average nanomicelles diameters, zeta potential, drug encapsulation efficiency and drug loading 
CUR-DAPMA, CUR-SPD, and CUR-SPM nanomicelles (Table S1); in vitro release behavior from 
free CUR, CUR-DPMA, CUR-SPD, and CUR-SPM nanomicelles (Figure S2); Western blots for 
HDAC2 and MMP2 expression following CUR-DAPMA, CUR-SPD, and CUR-SPM treatments. 
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